The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy

Istanbul University

Status: Completed

Conditions: Glomerulonephritis; Membranous Nephropathy; Nephrotic Syndrome

Treatments: Drug: lansoprazole, amoxicillin, clarithromycin

Study type: Interventional

Funder types: Other

Identifiers

NCT00983034

20061976

Details and patient eligibility

About

Membranous nephropathy (MN) may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). In this study, the presence of Helicobacter Pylori (H. pylori) antigen was investigated in renal tissue from needle biopsy samples, and the prevalence of H. pylori infection and the effects of H. pylori eradication on proteinuria level in patients with MN will be investigated.

Full description

Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. It is thought to be mainly a primary or idiopathic form; however, it may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). In this study, the presence of Helicobacter Pylori antigen was investigated in renal tissue from needle biopsy samples, and the prevalence of H. pylori infection and the effects of H. pylori eradication on proteinuria level in patients with MN will be investigated.

Enrollment: 70 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age between 18-70 years
• Nondiabetic patients
• Patients with primary glomerulonephritis
• Clinical diagnosis of membranous nephropathy, IgA nephropathy or focal segmental glomerulosclerosis confirmed by biopsy
• Glomerular filtration rate > 30 mL/min
• Patients who did not receive Helicobacter pylori eradication therapy within the last three months before enrollment in study

Exclusion criteria

• Patients with secondary glomerulonephritis
• Glomerular filtration rate < 30 mL/min
• Patients who received Helicobacter pylori eradication therapy within the last three months before enrollment in study
• Patients with a history of gastric surgery
• Patients without an informed consent

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

70 participants in 3 patient groups

Membranous nephropathy

Active Comparator group

Description:

Patients with primary membranous nephropathy diagnosed by biopsy

Treatment:

Drug: lansoprazole, amoxicillin, clarithromycin

IgA nephropathy

Active Comparator group

Description:

Patients with IgA nephropathy diagnosed by biopsy

Treatment:

Drug: lansoprazole, amoxicillin, clarithromycin

Focal segmental glomerulosclerosis

Active Comparator group

Description:

Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy

Treatment:

Drug: lansoprazole, amoxicillin, clarithromycin